News | July 09, 2024
Olink announces receipt of CMA clearance for proposed acquisition by Thermo Fisher
Shares and American Depositary Shares of Olink for $26.00 per Share
Shares and American Depositary Shares of Olink for $26.00 per Share
Felzartamab demonstrated positive interim results from the Phase 2 IgA nephropathy (IgAN) study
This plant is located at Baddi, Himachal Pradesh spread over an area of 2.85 acres
The transaction aligns with Lupin's strategy to grow its global presence in Specialty areas
This acquisition complements AstraZeneca’s leading oncology portfolio with the addition of the Fusion pipeline of RCs
Adds first-in-class investigational asset, NX-13, to AbbVie's pipeline with the potential to offer a novel approach to the treatment of ulcerative colitis (UC) and Crohn's disease (CD)
KarXT, Karuna’s lead asset, is a potential first-in-class treatment for Schizophrenia
Acquisition broadens oncology pipeline with a portfolio of novel T-cell engagers including HPN328 (MK-6070), an investigational delta-like ligand 3 (DLL3) targeting T-cell engager
The acquisition enriches AstraZeneca’s growing pipeline of cell therapies with GC012F
The acquisition will build on AstraZeneca’s expertise in respiratory syncytial virus
Subscribe To Our Newsletter & Stay Updated
